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Purpose: As COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities,
our purpose was to establish the CCV safety profile of indacaterol, a novel, inhaled, long-acting
b2-agonist for COPD.
Methods: The indacaterol clinical trial database comprised 4635 patients with moderate-to-
severe COPD enrolled into studies of 6 months’ duration treated with indacaterol,
placebo or other bronchodilators (formoterol, salmeterol, tiotropium). Adverse events
(AEs) were analysed overall and according to Anti-Platelet Trialists’ Collaboration (APTC)
criteria and baseline cardiovascular risk factors. A subset of patients had Holter moni-
toring.
Results: Compared with placebo, indacaterol did not increase the risk of CCV AEs; relative
risks were not significantly different for indacaterol versus other treatments. In all treat-
ment groups, including placebo, most CCV AEs occurred in patients with pre-existing
cardiovascular risk factors. The risk of APTC events (e.g. myocardial infarction, stroke,
cardiovascular-related death) was not significantly increased for indacaterol versus
placebo. The incidence of notable QTc interval increases >60 ms was low with all active
treatments (0e0.5%, versus 0.3% with placebo). Holter monitoring in the subset of patients
receiving indacaterol, tiotropium or placebo showed no clinically relevant effect of indaca-
terol or tiotropium relative to placebo on the development of arrhythmias. The number of
deaths adjusted for exposure was lower with all active treatments than with placebo, with
a trend to reduced risk with indacaterol (relative risk 0.30, p Z 0.054).1 7580 1101; fax: þ49 911 7580 1141.
erth.de (H. Worth).
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572 H. Worth et al.Conclusion: The overall CCV safety profile of indacaterol was similar to placebo and
comparable with other long-acting bronchodilators, providing reassurance for regular
long-term use of indacaterol in COPD.
Data for this analysis were pooled from three studies, registered at ClinicalTrials.gov as:
NCT00393458, NCT00463567 and NCT00567996.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Indacaterol is a novel, inhaled, long-acting b2-agonist
providing 24-h bronchodilation with once-daily dosing. In
November 2009, the European Union approved indacaterol
at doses of 150 and 300 mg once daily for use in patients
with COPD. Since indacaterol is intended for regular long-
term use, its cardio- and cerebrovascular (CCV) safety was
investigated during the clinical development programme
as part of a comprehensive evaluation of safety. This was
considered particularly important because b2-adrenoceptor
stimulation may increase heart rate and the risk of cardiac
arrhythmia,1 and because CCV diseases are common co-
morbidities in COPD patients.2e4
The present analysis quantifies the occurrence and risk
of CCV events and mortality in patients who entered studies
of least 6 months’ treatment duration with indacaterol in
the clinical development programme. Data from the
comparative treatment arms (placebo, tiotropium, for-
moterol and salmeterol) are included. Data for 6 months
were pooled from three separate clinical trials (two of 6
months’ and one of 12 months’ duration) that shared
a common methodology for evaluation of safety.5e8 Elec-
trocardiograms (ECGs) were assessed routinely in each
study by regular 12-lead monitoring, with a comprehensive
ECG evaluation by 24-h Holter monitoring in one study.6
Methods
The present analysis of safety is based on pooled data from
patients who enrolled in three phase III studies of at least 6
months’ duration. This time-frame provides a reasonable
number of patients and a sufficiently long treatment period
to be representative of the long-term nature of treatment.
In study 1,5 patients were treated with double-blind inda-
caterol 300 mg or 600 mg once daily (q.d.), formoterol 12 mg
twice daily (b.i.d.) or placebo for 52 weeks (data from up to
Day 182 included in the present analysis). In study 2,6
patients were treated with double-blind indacaterol 150 mg
or 300 mg q.d. or placebo, or open-label tiotropium 18 mg
q.d., for 26 weeks. All data from this study were included
here. Study 2 also had an initial dose-selection stage7 with
additional treatment arms (indacaterol 75 mg and 600 mg
q.d., and formoterol 12 mg b.i.d.). Those data were
included in the pooled data set apart from indacaterol
75 mg, since this is below the approved doses and was given
to a much smaller number of patients (127) than were in
the other treatment groups. In contrast, the 600 mg data, at
2e4 times the therapeutic dose, are informative from the
safety viewpoint. As part of the overall objective to eval-
uate thoroughly the cardiac safety of indacaterol, a subset
of patients in the second study6 underwent 24-h Holtermonitoring. In Study 3,8 patients were treated with double-
blind indacaterol 150 mg q.d., salmeterol 50 mg b.i.d. or
placebo for 26 weeks; all data were included. In all studies,
safety was monitored using identical methodology. Patients
were allowed to use concomitant inhaled corticosteroids at
a stable dose and regimen, and salbutamol as needed.
Patients
The three studies had identical entry criteria, and enrolled
male and female patients aged 40 years, with a diagnosis
of COPD,9 a smoking history of 20 pack-years, and post-
bronchodilator (salbutamol 400 mg) FEV1 <80% and 30%
predicted and FEV1/FVC <70%. Patients with concomitant
CCV conditions (including chronic atrial fibrillation [AF])
were not specifically excluded from the studies, unless
they had a clinically significant condition that might
have affected their safety, compliance or ability to
complete the study. Such conditions included, for example,
unstable ischaemic heart disease, arrhythmia (excluding
stable AF) and uncontrolled hypertension. Patients with
a history of long QT syndrome or a prolonged QTc interval at
baseline of >450/470 ms (males/females) were excluded,
as were patients receiving non-selective b-blockers,
cardiac anti-arrhythmics (classes Ia or III) or any drug with
the potential significantly to prolong the QT interval.
Evaluations and outcomes
CCV adverse events (AEs)
CCV AEs were defined as AEs described in any of the four
standardized MedDRA query (SMQ) groupings ‘arrhythmia’,
‘cardiac failure’, ‘ischaemic heart disease’ and ‘cerebro-
vascular disorders’. The SMQ system was developed as
a common standard by the Council for International Orga-
nizations of Medical Sciences (CIOMS, part of the World
Health Organization) to overcome the size and complexity
of MedDRA terminology when trying to retrieve cases
related to a specific safety aspect. The full list of preferred
terms included in the SMQ groups is provided in the
Appendix (see supplementary material). An SAE was
defined as an event that was fatal or life-threatening,
resulted in persistent or significant disability/incapacity,
constituted a congenital anomaly/birth defect, required
inpatient hospitalization or prolongation of existing hospi-
talization (unless hospitalization was for routine or unre-
lated reasons), or was medically significant (i.e. an event
that jeopardized the patient or required medical or surgical
intervention to prevent one of the outcomes listed above).
The incidence of CCV AEs was also summarized according
to the presence and number of baseline cardiovascular risk
factors: age 65 years; body mass index (BMI) >30 kg/m2;
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of, or current, CCV condition, hypertension or hyper-
lipidaemia.
Adverse events were further analysed according to the
Anti-Platelet Trialists’ Collaboration (APTC) criteria. These
criteria are designed to capture the ‘hard’ or more objec-
tive endpoints that define a serious vascular event (e.g.
myocardial infarction, stroke, and/or cardiovascular-
related deaths or deaths from an unknown cause).10 They
exclude ‘softer’ or less well-defined endpoints (e.g. angina
pectoris) that can be difficult to measure objectively. Thus,
the number of terms that are used to define the APTC
events (see Appendix) is relatively small compared with the
number of terms used in the SMQ approach.
ECG evaluations
Data were collected while patients were on treatment and
for 7 days after treatment discontinuation. Standard
12-lead ECG recordings were performed at 1 h post-dose at
several clinic visits during all the studies. The derived
corrected QT interval (QTc) is presented here, with
correction applied according to Fridericia’s formula, this
being the preferred method for treatments that potentially
increase heart rate.11,12
Holter monitoring was performed in a subset of approx-
imately 100 patients per treatment group in the second
study at baseline and after 2, 12 and 26 weeks of treatment.
Data from the Holter monitors were processed and inter-
preted by a cardiologist at the central ECG laboratory. The
24-h daily mean heart rate, hourly mean heart rate, and
frequency of ventricular and supraventricular arrhythmic
events were summarized by treatment for each visit sepa-
rately. Only patients with at least 18 h of analysed time at
baseline and at least one post-baseline visit were included.
Vital signs
Vital signs (sitting pulse and sitting systolic and diastolic
blood pressure) were measured in each study at baseline
(25 min pre-dose) and at clinic visits after 2, 4, and 12
weeks and 6 months (pre-dose and 1 h post-dose).
Deaths
Deaths that occurred while patients were receiving treat-
ment and for 30 days after treatment discontinuation were
analysed.
Statistical analysis
The incidence of CCV AEs and serious adverse events (SAEs)
and the AEs by APTC criteria were calculated. In this anal-
ysis, incidencewas defined as counts of patientswith at least
one event. The relative risk (RR) and associated 95% confi-
dence intervals were calculated based on these counts with
Fisher’s exact test used to calculate the pair-wise p-value for
relative risk for each active treatment group versus placebo.
The number of deaths and CCV-related deaths were pre-
sented adjusted for exposure, with relative risk and associ-
ated confidence intervals obtained from a Poisson regression
model. The model contained treatment as an explanatory
variable. All other data are summarized as counts and
percentages and presented without statistical analysis.Results
The 6-month safety population consisted of 4635 patients
with moderate and severe COPD and a mean age of 64 years.
Demographic and disease characteristics were similar across
the treatment groups (Supplementary Table 1). Over 90% of
patients across the treatment groups had one ormore CV risk
factors at baseline and approximately 40% had three or more
CV risk factors; the frequency was evenly distributed across
the groups. Exposure to study drug treatment was reason-
ably uniform across the groups (Supplementary Table 1).
Adverse events
CCV AEs and SAEs
Table 1 shows the incidence of CCV AEs and SAEs. There was
no statistically significant increase in the risk for CCV AEs
with indacaterol compared with placebo(p-values of 0.06,
0.09 and 1.00 for the 150, 300 and 600 mg doses), nor with
formoterol or salmeterol. Tiotropium was associated with
an increased relative risk versus placebo (p < 0.05). Neither
the incidence nor the relative risk increased numerically
with increasing dose of indacaterol. CCV SAEs followed
a similar pattern (Table 1), with no significant increase in
relative risk versus placebo for any active treatment.
When treatment groups were combined for the purposes
of analysis, the relative risk of experiencing a CCV AE with
indacaterol (combined doses of 150, 300, 600 mg) was not
significantly different from that associated with the
combined active comparators (combination of formoterol,
tiotropium and salmeterol) (relative risk of incidence 0.98
[95% CI 0.72, 1.34]; p Z 0.934) or relative to all other
treatments including placebo (relative risk 1.13 [95% CI
0.86, 1.47]; pZ 0.389). Findings were similar for CCV SAEs
(corresponding relative risks of 1.22 [95% CI 0.68, 2.17],
p Z 0.563, and 1.23 [95% CI 0.76, 1.99], p Z 0.456).
CCV AEs in SMQ groupings
Table 2 shows the incidence of CCV AEs and SAEs by SMQ
grouping. In all treatment groups, including placebo, the
majority of AEs were in the grouping ‘arrhythmia’. The
incidenceof SMQarrhythmiaAEswas similarwith indacaterol
(2.2e2.9%) compared with the other treatments (2.0e2.7%
with formoterol, salmeterol and placebo, and 4.1% with
tiotropium), anddid not increasenumericallywith increasing
indacaterol dose. Within the SMQ grouping ‘arrhythmia’, AF
occurred as an SAE in three patients receiving indacaterol
150 mg, one patient receiving salmeterol, three patients
receiving tiotropium and three receiving placebo. Also in the
arrhythmia grouping, ventricular tachycardia (VT) as an SAE
occurred in one patient receiving indacaterol 150 mg and one
placebo patient. The three cases of AF as an SAE with inda-
caterol 150 mg weremild or moderate in severity; two events
were transient (1 or 2 days) and one was continuing. The
patient with AF during salmeterol treatment was diagnosed
with bacterial sepsis, followed by rapid (transient) AF. The
three cases of AF with tiotropium were moderate (one) or
severe (two); two cases were transient and the third was
continuing. The case of VT with indacaterol was an asymp-
tomatic finding revealed on the Holter report, was non-sus-
tained (lasting for 2 days), and was reported as severe.
Table 1 Incidence of CCV AEs and SAEs (6-month safety population).
Indacaterol
150 mg
Indacaterol
300 mg
Indacaterol
600 mg
Indacaterol
doses
combined
Formoterol Salmeterol Tiotropium Placebo
N 746 853 547 2146 556 333 415 1185
Total patient-years 331.04 379.31 222.52 932.87 227.49 149.79 180.23 487.41
No. of CCV AEs 46 56 24 126 28 19 33 54
Number of patients with
CCV AEs, n (%)
39
(5.2)
43
(5.0)
18
(3.3)
100
(4.7)
22
(4.0)
16
(4.8)
24
(5.8)
41
(3.5)
Relative risk vs placebo
of experiencing
1 CCV AE (95% CI)
1.51
(0.98,
2.32)
1.46
(0.96,
2.22)
0.95
(0.55,
1.64)
1.35
(0.94,
1.92)
1.14
(0.69,
1.90)
1.39
(0.79,
2.44)
1.67
(1.02,
2.73)
p-value 0.061 0.090 1.000 0.106 0.585 0.255 0.044
No. of CCV SAEs 15 15 9 39 5 7 12 16
Number of patients with
CCV SAEs, n (%)
15
(2.0)
12
(1.4)
7
(1.3)
34
(1.6)
3
(0.5)
5
(1.5)
9
(2.2)
15
(1.27)
Relative risk vs placebo
of experiencing
1 CCV SAE (95% CI)
1.59
(0.78,
3.23)
1.11
(0.52,
2.36)
1.01
(0.42,
2.47)
1.25
(0.69,
2.29)
0.43
(0.12,
1.47)
1.19
(0.43,
3.24)
1.71
(0.76,
3.89)
p-value 0.256 0.845 1.000 0.549 0.208 0.785 0.238
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factors at baseline
Supplementary Table 2 shows the incidence of CCV AEs
according to the presence of cardiovascular risk factors at
baseline. With all treatments, including placebo, there was
a numerical trend to increased CCV AE incidence with
increasing number of baseline risk factors (these results
were not analysed statistically). Among all patients with 1
or more cardiovascular risk factors, the incidence of CCV
AEs in the active treatment groups was either similar to
placebo (indacaterol 600 mg and placebo, both 3.3%) or
slightly higher (formoterol, 4.1%; salmeterol, 4.8%; inda-
caterol 300 mg, 5.4%; indacaterol 150 mg, 5.6%; tiotropium,
5.8%). CCV SAEs (not shown) were numerically most
common in patients with three or more baseline cardio-
vascular risk factors in all treatment groups apart from
indacaterol 600 mg, where the SAEs were divided between
patients with one or two risk factors. The incidence of CCV
AEs according to individual cardiovascular risk factors isTable 2 Number of patients (%) with CCV AEs and SAEs by SMQ
Indacaterol
150 mg
Indacaterol
300 mg
In
6
N 746 853 5
CCV AEsa
Arrhythmia SMQ 22 (2.9) 24 (2.8) 1
Cardiac failure SMQ 3 (0.4) 4 (0.5) 3
Ischaemic heart disease SMQ 10 (1.3) 12 (1.4) 5
Cerebrovascular disorders SMQ 4 (0.5) 3 (0.4) 0
CCV SAEsa
Arrhythmia SMQ 5 (0.7) 1 (0.1) 2
Cardiac failure SMQ 0 2 (0.2) 1
Ischaemic heart disease SMQ 7 (0.9) 6 (0.7) 5
Cerebrovascular disorders SMQ 3 (0.4) 3 (0.4) 0
a Patients may be counted more than once across different SMQ groshown in Fig. 1. Although not analysed statistically, the
presence of a pre-existing CCV condition appeared to have
the greatest influence, irrespective of treatment, on
whether a patient subsequently experienced a CCV AE. The
influence of other cardiovascular risk factors was much
lower, and was not consistent between treatments.
Analysis of AEs according to APTC criteria
Supplementary Table 3 shows the incidence of AEs defined
by APTC criteria. With the stringent criteria for these ‘hard’
endpoints, numbers were low overall. There was no
significant increase in risk relative to placebo for indaca-
terol doses individually or combined (150, 300, 600 mg).
Neither incidence nor relative risk versus placebo increased
numerically with increasing indacaterol dose. There was no
significant increase in risk when all indacaterol doses
combined were compared with all other treatments
combined including placebo (relative risk of 1.27 [95% CI
0.56, 2.86]; p Z 0.68).grouping (6-month safety population).
dacaterol
00 mg
Formoterol Salmeterol Tiotropium Placebo
47 556 333 415 1185
2 (2.2) 11 (2.0) 9 (2.7) 17 (4.1) 26 (2.2)
(0.5) 7 (1.3) 2 (0.6) 2 (0.5) 4 (0.3)
(0.9) 4 (0.7) 6 (1.8) 7 (1.7) 6 (0.5)
1 (0.2) 0 2 (0.5) 7 (0.6)
(0.4) 1 (0.2) 2 (0.6) 4 (1.0) 4 (0.3)
(0.2) 1 (0.2) 0 0 2 (0.2)
(0.9) 1 (0.2) 4 (1.2) 4 (1.0) 5 (0.4)
0 0 1 (0.2) 4 (0.3)
upings.
0 
2 
4 
6 
8 
10 
IND 
150 
IND 
300 
IND 
600 
FORM SALM TIO PBO 
Age <65 Age 
0 
2 
4 
6 
8 
10 
IND 
150 
IND 
300 
IND 
600 
FORM SALM TIO PBO 
BMI BMI >30 
Patients (%) Patients (%) 
0 
2 
4 
6 
8 
10 
IND 
150 
IND 
300 
IND 
600 
FORM SALM TIO PBO 
No history of DM History of DM 
0 
2 
4 
6 
8 
10 
12 
IND 
150 
IND 
300 
IND 
600 
FORM SALM TIO PBO 
No CCV condition 
CCV condition 
0 
2 
4 
6 
8 
10 
IND 
150 
IND 
300 
IND 
600 
FORM SALM TIO PBO 
No hyperlipidaemia 
Hyperlipidaemia 
0 
2 
4 
6 
8 
10 
IND 
150 
IND 
300 
IND 
600 
FORM SALM TIO PBO 
No hypertension 
Hypertension 
0 
2 
4 
6 
8 
10 
IND 
150 
IND 
300 
IND 
600 
FORM  SALM TIO PBO 
Ex-smoker Smoker 
≥65 ≤30
Figure 1 Percentage of patients with CCV AEs according to presence or not of cardiovascular risk factors at baseline.
IND Z indacaterol (150, 300 and 600 Z mg doses); FORM Z formoterol; SALM Z salmeterol; TIO Z tiotropium; PBO Z placebo;
BMI Z body mass index (kg/m2); DM Z diabetes mellitus.
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6-Month safety population
Few patients in any treatment group experienced notable
increases from baseline (>60 ms) in QTc interval or notable
absolute values (>500 ms) (Table 3). Two patients receiving
indacaterol 150 mg recorded QTc interval values >500 ms.One of these patients had a normal baseline value but a high
value pre-treatment on Day 1 (452 ms) and was later diag-
nosed with pancreatic adenocarcinoma. The other patient
had a high baseline value (493 ms), was being treated for
cardiac failure that was active at the start of the study, and
was receiving amiodarone, an anti-arrhythmic known to
prolong the QTc interval. The tiotropiumpatientwith a value
Table 3 Number (%) of patients with clinically notable QTc(F) increases from baseline or absolute values, measured at any
time post-baseline.
Indacaterol
150 mg N Z 746
Indacaterol
300 mg N Z 853
Indacaterol
600 mg N Z 547
Formoterol
N Z 556
Salmeterol
N Z 333
Tiotropium
N Z 415
Placebo
N Z 1185
Increase 30e60 ms 70 (9.4) 82 (9.8) 45 (8.4) 49 (9.1) 15 (4.5) 39 (9.5) 90 (7.7)
Increase >60 ms 2 (0.3) 1 (0.1) 1 (0.2) 0 1 (0.3) 2 (0.5) 3 (0.3)
Value >450/470 msa
(M/F)
31 (4.2) 38 (4.5) 27 (5.0) 25 (4.5) 6 (1.8) 21 (5.1) 52 (4.4)
Value >500 msa 2 (0.3) 0 0 0 0 1 (0.2) 0
Increases are measured from the mean of the values at 25 min pre-dose at baseline to any time point post-baseline when the notable
value occurred. Percentages are calculated using total number of patients with baseline and post-baseline values as denominator.
a Includes both patients with newly occurring value at any time post-baseline and patients with a baseline value meeting the criterion
and a worse post-baseline value.
576 H. Worth et al.>500 ms also had a high baseline value (500 ms) and had
received treatment for hypertension.
24-h ECG Holter monitoring subset
In this subset of patients from one of the studies,6 the 24-h
mean heart rate did not differ statistically significantly
among the treatments (indacaterol 150 mg, indacaterol
300 mg, tiotropium and placebo) at any time point, with
differences from placebo (at Weeks 2, 12 and 26) of
between 0.5 and 0.3 bpm for indacaterol 150 mg, between
0.4 and 1.0 bpm for indacaterol 300 mg, and between 0.3
and 1.6 bpm for tiotropium.
Other Holter data were not analysed statistically. For
indacaterol 150 and 300 mg, tiotropium and placebo, no
meaningful changes from baseline in the number of sinus
pauses were seen at Weeks 2, 12 or 26. The proportion of
patients with a pro-arrhythmic response was numerically
similar across the active treatments and highest in the
tiotropium group (Supplementary Table 4).
Patients with chronic AF were permitted to enter this
study. Despite this, very low rates of AF were seen either atTable 4 Deaths (all causes) and CCV-related deaths (confirmed
relative risk calculations (6-month safety population).
Indacaterol
doses combined
For
N 2146 556
Total patient-years 932.9 227
No. of deaths (%) 4a (0.19) 2 (0
Deaths per 1000 patient-years 4.3 8.8
Relative risk of death vs
placebo (risk ratio, 95% CI)
0.30
(0.09, 1.02)
0.6
(0.
p-value 0.054 0.5
No. of CCV-related deaths 3a 1b
CCV deaths per 1000
patient-years
3.22 4.4
Relative risk of CCV death vs
placebo (risk ratio, 95% CI)
0.31
(0.08, 1.31)
0.4
(0.
p-value 0.112 0.4
a Three CCV-related deaths, due to cardiac arrest (150 mg), sudden
due to COPD exacerbation occurred during follow-up (600 mg). Cause
b sudden death.
c arteriosclerosis.
d cardio-respiratory arrest, myocardial infarction, sudden death (nbaseline or post-baseline in the indacaterol (three or fewer
patients at any time point) and tiotropium groups (two or
fewer patients at any time point), and only one placebo
patient had AF (Week 26).
Overall, the rates of specific arrhythmias were numeri-
cally largely similar in the indacaterol and tiotropium
groups. Compared with indacaterol and tiotropium,
patients in the placebo group had fewer episodes of non-
sustained VT but more of the frequent short episodes of
supraventricular tachycardia (Supplementary Table 5). Only
one patient (in the indacaterol 150 mg group) experienced
a serious cardiac arrhythmia (sustained VT at Week 26). At
the baseline monitoring, this patient had recorded frequent
ventricular premature contractions (534 over 24 h). The VT
at Week 26 was sustained for 44 beats and was not reported
as an AE by the investigator. There were no associated
symptoms or biochemical abnormalities and all ECGs were
categorized as normal. The patient did not discontinue
from the study. There were no episodes of ventricular
fibrillation/flutter, torsade de pointes, or intermittent
junctional rhythm.or possibly/probably CCV-related) adjusted for exposure with
moterol Salmeterol Tiotropium Placebo
333 415 1185
.5 149.8 180.2 487.4
.36) 0 2 (0.48) 7 (0.59)
0 11.1 14.4
1
13, 2.95)
0.00
(0.00, N)
0.77
(0.16, 3.72)
41 NA 0.748
0 1c 5d
0 0 5.55 10.26
3
05, 3.67)
0.00
(0.00, N)
0.54
(0.06, 4.63)
39 NA 0.575
death (150 mg), cardiac arrest (300 mg); a non-CCV-related death
s of death were recorded as.
Z 2), multi-organ failure.
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Effects on vital signs were numerically similar with all
active treatments and placebo. Maximum post-baseline
changes from baseline with all treatments were 6e8 beats/
min in sitting pulse, 10.4e12.0 mmHg in sitting systolic
blood pressure and 6.0e7.6 mmHg in sitting diastolic blood
pressure, with placebo values in the middle of these ranges.
Deaths
Deaths and CCV-related deaths are shown in Table 4. The
adjusted (all-cause) mortality rate (standardized per 1000
patient-years) was zero with salmeterol, 4.3 with indaca-
terol (all doses combined), 8.8 with formoterol and 11.1
with tiotropium, compared with 14.4 with placebo. None of
the differences versus placebo was statistically significant,
although there was a trend towards risk reduction with
indacaterol versus placebo (p Z 0.054).
Discussion
The profile of CCV safety with indacaterol compared
favourably with the other bronchodilators evaluated.
Treatment with indacaterol was not associated with any
statistically significant increase in risk compared with
placebo for CCV AEs and SAEs, and there was no increase in
incidence or risk with increasing indacaterol doses. Among
the other active treatments, only tiotropium was associ-
ated with a statistically significant increase in relative risk
of CCV AEs compared with placebo. None of the active
treatments was associated with a significant increase in risk
of CCV SAEs relative to placebo, although the low incidence
of SAEs meant that the power to detect any differences
between treatments in CCV SAEs was lower than for CCV
AEs. When the indacaterol treatment groups and all other
treatment groups were each combined for the purposes of
analysis, the relative risk of CCV AEs and SAEs for indaca-
terol was not significantly increased compared with all
other bronchodilators, or when placebo was included in the
latter group. Although the combined group of ‘all other
treatments’ may not be sufficiently homogenous for a fair
comparison, it provides a useful indication in real-world
terms of the expected CCV safety of a novel bronchodilator
in comparison with established and currently available
treatments. The system of SMQ grouping allows further
scrutiny of the CCV safety profile of treatment. These SMQ
groupings were devised specifically for the investigation of
CCV safety of indacaterol in order to show more clearly any
potential safety signal that might otherwise be obscured by
the multitude of similar and overlapping terms that are
used to define relevant events. The rate of CCV AEs during
treatment with indacaterol and the other treatments,
including placebo, was numerically highest in the
‘arrhythmia’ category. However, serious arrhythmias
occurred infrequently with treatment. The high incidence
of arrhythmias in the placebo group reflects the common
occurrence of arrhythmias in patients with COPD.3,13 AF
and VT, which may be regarded as the most important
arrhythmias, were uncommon as SAEs with indacaterol, and
most cases were mild or moderate, and transient. The case
of VT reported as an SAE with indacaterol was anasymptomatic finding noted on Holter monitoring. It should
be noted that patients with chronic AF were not excluded
from these studies, although the need to ensure patient
safety would likely have resulted in the exclusion of
patients with unstable or acute CCV conditions.
In the SMQ category of cardiac failure, the incidence of
CCV AEs was numerically highest in the formoterol group.
Examination of individual case records indicated that the
AE was serious in only one of the seven affected patients
and was not thought by the investigator to be related to
treatment. The incidence of events within the ‘ischaemic
heart disease’ SMQ grouping was generally numerically
similar among the active treatments and a little higher than
with placebo. Among the 18 SAEs in this grouping that
occurred during indacaterol treatment, most cases (15;
83%) were considered by the investigators to be unrelated
to study treatment when individual case records were
examined. The incidence of AEs and SAEs in the SMQ
grouping ‘cerebrovascular disorders’ was low and numeri-
cally comparable among active and placebo treatments.
With all active treatments, the analysis of APTC events
(comprising non-fatal myocardial infarction, non-fatal
stroke, and death from a vascular or unknown cause)
showed no significant increase in risk relative to placebo.
Most CCV AEs with indacaterol occurred in patients with
pre-existing cardiovascular risk factors, while with other
treatments the CCV AEs tended to be more evenly distrib-
uted between patients with and without pre-existing
cardiovascular risk factors. There was no discernible
numerical pattern of effect in the relatively small
subgroups divided according to numbers of cardiovascular
risk factors, nor when all the risk factor subgroups were
combined. Furthermore, the presentation of adverse
events in this way may be oversimplistic, given the possi-
bility that some cardiovascular risk factors may be associ-
ated with more risk than others.
Prolongation of QTc interval (which reflects increased
risk of cardiac arrhythmia) was rare. The Holter monitoring
results showed no clinically relevant effects of indacaterol
on heart rate, ECG intervals, morphology and interpreta-
tion, or on pro-arrhythmia indicators, nor any imbalance
between treatments for VT. A lack of pro-arrhythmic
potential with indacaterol was also demonstrated in
a specific study of QTc interval in healthy subjects using
active and placebo controls,14 which showed no dose-
response with indacaterol doses in the range 150e600 mg. A
study in which the 300 and 600 mg doses of indacaterol were
evaluated for 1 year in patients with COPD also reported
low arrhythmogenic potential and good overall safety.5
Although short-acting b2-agonists are typically reported to
have the potential of increasing heart rate and the risk of
arrhythmia,1,15 we found the long-acting agents, including
indacaterol, to have little or no effect on heart rate or
arrhythmias. Similar findings have been reported
previously.16e19
There was some indication of increased CCV AE incidence
with tiotropium. However, these findings should be viewed
with caution when compared with other published analyses
of tiotropium safety, owing to the small size of this treat-
ment group (415 patients) and the fact that the tiotropium
treatment was administered open-label (blinded tiotropium
was not available). Previous suggestions of an increased risk
578 H. Worth et al.of death, heart attack or stroke in patients using tiotropium
or other anticholinergic drugs20 were later discounted21 and
appeared to be resolved following the results of a 4-year
study in 5993 COPD patients which showed no significant
increase with tiotropium relative to placebo in the risk of
stroke, heart attack, or cardiovascular death.22 The most
recent report of the tiotropium safety database, including
10,846 patients treated with tiotropium, showed rate ratios
compared with placebo of below or close to 1 for cardiac
and vascular AEs.23
Individuals with COPD are generally middle-aged or
elderly, and many are current or ex-smokers. They have
a higher prevalence of cardiovascular risk factors and
cardiovascular diseases, and are at increased risk for hospi-
talizations and deaths due to cardiovascular diseases.2e4
While we acknowledge that the patients in the present
analysis are not precisely representative of the general
COPD population, we would point out that the clinical
studies did not exclude patients for reasons of existing CCV
conditions, whichwere present in 20% of patients. Other CCV
risk factors such as hypertension (50%), hyperlipidaemia
(35%) and high BMI (23%) were common; approximately half
the patients were older than 65 years, and all patients were
required to have a substantial smoking history of at least 20
pack-years. We believe therefore that the present analysis
provides a useful indication of the CCV safety of indacaterol
in clinical use.
This analysis found no increased risk with indacaterol,
relative to placebo, of all-cause or CCV-related mortality
with indacaterol, nor with any of the other treatments
evaluated. As with CCV SAEs, the low incidence of deaths
lessened the power to detect any differences between
treatments. In all cases the relative risk for indacaterol
compared with placebo was below 1. The number of deaths
was lower with indacaterol and the risk reduction
approached statistical significance. It will be interesting to
see if a significant reduction in risk emerges as the safety
database expands during the further development of
indacaterol. Our mortality results are in line with previous
findings of no increase, or non-significant reductions, in
CCV and all-cause mortality in COPD patients treated with
a long-acting b2-agonist or tiotropium.
24e26
Our study adds to the increasing body of clinical
evidence that long-acting bronchodilators used at thera-
peutic doses in stable COPD have a reassuring CCV safety
profile and do not further add to CCV mortality or morbidity
in patients with COPD.27,28 Indacaterol demonstrated no
apparent potential for increased risk even with the highest
evaluated dose of 600 mg, providing a good margin of
confidence when prescribing once-daily indacaterol.
In conclusion, the CCV safety profile of indacaterol
compares favourably with existing long-acting bronchodi-
lator treatments. The acceptable CCV safety profile of
indacaterol in a relevant patient population should provide
reassurance to potential prescribers of a treatment
designed for long-term use in patients with COPD.Funding
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